Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8772 |
High Similarity |
NPD8434 |
Phase 2 |
0.8354 |
Intermediate Similarity |
NPD5760 |
Phase 2 |
0.8354 |
Intermediate Similarity |
NPD5761 |
Phase 2 |
0.8047 |
Intermediate Similarity |
NPD5537 |
Clinical (unspecified phase) |
0.7753 |
Intermediate Similarity |
NPD6764 |
Approved |
0.7753 |
Intermediate Similarity |
NPD6765 |
Approved |
0.7706 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7674 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7582 |
Intermediate Similarity |
NPD6784 |
Approved |
0.7582 |
Intermediate Similarity |
NPD6785 |
Approved |
0.7582 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7556 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7525 |
Intermediate Similarity |
NPD8404 |
Phase 2 |
0.75 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7473 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7442 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.741 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7386 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7356 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7356 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7345 |
Intermediate Similarity |
NPD1247 |
Approved |
0.7293 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7283 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7278 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7258 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7257 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7238 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7232 |
Intermediate Similarity |
NPD919 |
Approved |
0.7228 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7225 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7222 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7216 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7216 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7213 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.72 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7198 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7182 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7175 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7175 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7168 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7151 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7151 |
Intermediate Similarity |
NPD8407 |
Phase 2 |
0.7151 |
Intermediate Similarity |
NPD920 |
Approved |
0.7143 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7143 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7135 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7126 |
Intermediate Similarity |
NPD1471 |
Phase 3 |
0.7111 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7097 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7097 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7092 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7081 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7081 |
Intermediate Similarity |
NPD8368 |
Discontinued |
0.7065 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7056 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7043 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7041 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7035 |
Intermediate Similarity |
NPD642 |
Clinical (unspecified phase) |
0.7033 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7024 |
Intermediate Similarity |
NPD2343 |
Clinical (unspecified phase) |
0.7017 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7011 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7006 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6973 |
Remote Similarity |
NPD7472 |
Approved |
0.6957 |
Remote Similarity |
NPD7799 |
Discontinued |
0.6949 |
Remote Similarity |
NPD37 |
Approved |
0.6939 |
Remote Similarity |
NPD6782 |
Approved |
0.6939 |
Remote Similarity |
NPD6780 |
Approved |
0.6939 |
Remote Similarity |
NPD6781 |
Approved |
0.6939 |
Remote Similarity |
NPD6777 |
Approved |
0.6939 |
Remote Similarity |
NPD6779 |
Approved |
0.6939 |
Remote Similarity |
NPD6778 |
Approved |
0.6939 |
Remote Similarity |
NPD6776 |
Approved |
0.6936 |
Remote Similarity |
NPD2532 |
Approved |
0.6936 |
Remote Similarity |
NPD2533 |
Approved |
0.6936 |
Remote Similarity |
NPD2534 |
Approved |
0.6927 |
Remote Similarity |
NPD4966 |
Approved |
0.6927 |
Remote Similarity |
NPD4965 |
Approved |
0.6927 |
Remote Similarity |
NPD4967 |
Phase 2 |
0.6923 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6919 |
Remote Similarity |
NPD7236 |
Approved |
0.6919 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD6273 |
Approved |
0.6885 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6882 |
Remote Similarity |
NPD1549 |
Phase 2 |
0.6881 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6881 |
Remote Similarity |
NPD7874 |
Approved |
0.6875 |
Remote Similarity |
NPD7907 |
Approved |
0.6868 |
Remote Similarity |
NPD6959 |
Discontinued |
0.6868 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6865 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6865 |
Remote Similarity |
NPD7228 |
Approved |
0.6864 |
Remote Similarity |
NPD2796 |
Approved |
0.6864 |
Remote Similarity |
NPD6099 |
Approved |
0.6864 |
Remote Similarity |
NPD6100 |
Approved |
0.686 |
Remote Similarity |
NPD4111 |
Phase 1 |
0.686 |
Remote Similarity |
NPD4665 |
Approved |
0.686 |
Remote Similarity |
NPD6190 |
Approved |
0.6851 |
Remote Similarity |
NPD6234 |
Discontinued |
0.6834 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6834 |
Remote Similarity |
NPD7697 |
Approved |
0.6834 |
Remote Similarity |
NPD7698 |
Approved |
0.6826 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6824 |
Remote Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.6824 |
Remote Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.6823 |
Remote Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.6823 |
Remote Similarity |
NPD8435 |
Approved |
0.6823 |
Remote Similarity |
NPD8360 |
Approved |
0.6823 |
Remote Similarity |
NPD8361 |
Approved |
0.6818 |
Remote Similarity |
NPD7239 |
Suspended |
0.6816 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6809 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.68 |
Remote Similarity |
NPD7870 |
Phase 2 |
0.68 |
Remote Similarity |
NPD7871 |
Phase 2 |
0.68 |
Remote Similarity |
NPD1512 |
Approved |
0.6782 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.678 |
Remote Similarity |
NPD7458 |
Discontinued |
0.678 |
Remote Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.6766 |
Remote Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.6765 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6765 |
Remote Similarity |
NPD7801 |
Approved |
0.6761 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.675 |
Remote Similarity |
NPD7497 |
Discontinued |
0.6744 |
Remote Similarity |
NPD1243 |
Approved |
0.6744 |
Remote Similarity |
NPD2800 |
Approved |
0.6743 |
Remote Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.674 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6738 |
Remote Similarity |
NPD8470 |
Clinical (unspecified phase) |
0.673 |
Remote Similarity |
NPD5619 |
Clinical (unspecified phase) |
0.6725 |
Remote Similarity |
NPD5762 |
Approved |
0.6725 |
Remote Similarity |
NPD5763 |
Approved |
0.672 |
Remote Similarity |
NPD7240 |
Approved |
0.6716 |
Remote Similarity |
NPD8319 |
Approved |
0.6716 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6706 |
Remote Similarity |
NPD7033 |
Discontinued |
0.6705 |
Remote Similarity |
NPD3750 |
Approved |
0.6686 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6686 |
Remote Similarity |
NPD1511 |
Approved |
0.6684 |
Remote Similarity |
NPD6535 |
Approved |
0.6684 |
Remote Similarity |
NPD6534 |
Approved |
0.6667 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6667 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD2403 |
Approved |
0.6667 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6649 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6647 |
Remote Similarity |
NPD3268 |
Approved |
0.6647 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6647 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6633 |
Remote Similarity |
NPD8285 |
Discontinued |
0.663 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6628 |
Remote Similarity |
NPD2344 |
Approved |
0.6627 |
Remote Similarity |
NPD6832 |
Phase 2 |
0.6617 |
Remote Similarity |
NPD3057 |
Approved |
0.6617 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6616 |
Remote Similarity |
NPD8485 |
Approved |
0.6616 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.6609 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6608 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6608 |
Remote Similarity |
NPD3748 |
Approved |
0.6607 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6602 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6602 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.66 |
Remote Similarity |
NPD4107 |
Approved |
0.6587 |
Remote Similarity |
NPD7095 |
Approved |
0.6585 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6559 |
Remote Similarity |
NPD5711 |
Approved |
0.6559 |
Remote Similarity |
NPD6808 |
Phase 2 |
0.6559 |
Remote Similarity |
NPD5710 |
Approved |
0.6557 |
Remote Similarity |
NPD8155 |
Clinical (unspecified phase) |
0.655 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6548 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6546 |
Remote Similarity |
NPD8424 |
Clinical (unspecified phase) |
0.6535 |
Remote Similarity |
NPD2972 |
Approved |
0.6535 |
Remote Similarity |
NPD3533 |
Approved |
0.6529 |
Remote Similarity |
NPD447 |
Suspended |
0.6517 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6517 |
Remote Similarity |
NPD8486 |
Clinical (unspecified phase) |
0.6517 |
Remote Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.6514 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6514 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6508 |
Remote Similarity |
NPD2163 |
Approved |
0.6497 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6494 |
Remote Similarity |
NPD2424 |
Discontinued |
0.6492 |
Remote Similarity |
NPD5953 |
Discontinued |
0.6491 |
Remote Similarity |
NPD1607 |
Approved |
0.6489 |
Remote Similarity |
NPD4575 |
Clinical (unspecified phase) |
0.6485 |
Remote Similarity |
NPD4482 |
Phase 3 |
0.6477 |
Remote Similarity |
NPD2309 |
Approved |
0.6477 |
Remote Similarity |
NPD2354 |
Approved |
0.6477 |
Remote Similarity |
NPD3887 |
Approved |
0.6474
|
Remote Similarity |
NPD7286 |
Phase 2 |